Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.53 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.49 |
| ▸ | NPC1 | O15118 | 4/20 | 0.48 |
| ▸ | RAB9A | P51151 | 4/20 | 0.48 |
| ▸ | MEN1 | O00255 | 3/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.48 |
| ▸ | GAA | P10253 | 2/20 | 0.48 |
| ▸ | MAPT | P10636 | 2/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.48 |
| ▸ | CCR6 | P51684 | 1/20 | 0.48 |
| ▸ | CXCR2 | P25025 | 3/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.45 |
| ▸ | KCNMA1 | Q12791 | 2/20 | 0.45 |
| ▸ | TP53 | P04637 | 1/20 | 0.45 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11091688 | 0.85 | CXCR2 (0.57) | NPC1RAB9AMEN1KMT2AGAA | |
| SCHEMBL27967987 | 0.82 | ALDH1A1 (0.54) | ALDH1A1NPC1RAB9AMEN1KMT2A | |
| SCHEMBL27968138 | 0.81 | CXCR2 (0.54) | ALDH1A1HSP90AA1MAPTMAPK1CXCR2 | |
| SCHEMBL5383722 | 0.78 | KDM4E (0.54) | ALDH1A1NPC1RAB9AMEN1KMT2A | |
| SCHEMBL304891 | 0.77 | CXCR2 (0.54) | ALDH1A1NPC1RAB9AMEN1KMT2A | |
| SCHEMBL24021599 | 0.76 | LMNA (0.62) | ALDH1A1NPC1RAB9AMEN1KMT2A | |
| SCHEMBL16148164 | 0.76 | RORC (0.60) | ALDH1A1NPC1RAB9AMEN1KMT2A | |
| SCHEMBL14514318 | 0.75 | CXCR2 (0.52) | ALDH1A1HSP90AA1NPC1RAB9AKMT2A | |
| SCHEMBL1920752 | 0.75 | CXCR2 (0.52) | ALDH1A1NPC1RAB9AMEN1KMT2A | |
| SCHEMBL9631014 | 0.75 | ALDH1A1 (0.69) | ALDH1A1NPC1RAB9AGAAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120172292-A1 | METHOD FOR PROTECTION OF ANTIMICROBIAL AND ANTICANCER DRUGS FROM INACTIVATION BY NITRIC OXIDE | NEW YORK UNIVERSITY (US) | 2012-07-05 | — | — | US | disclosed |
| US-20090291923-A1 | TRIOXANE DIMERS HAVING HIGH ANTICANCER AND LONG-LASTING ANTIMALARIAL ACTIVITIES | JOHNS HOPKINS UNIVERSOTY (US) | 2009-11-26 | — | — | US | disclosed |
| US-20090291923-A1 | TRIOXANE DIMERS HAVING HIGH ANTICANCER AND LONG-LASTING ANTIMALARIAL ACTIVITIES | JOHNS HOPKINS UNIVERSOTY (US) | 2009-11-26 | — | — | US | disclosed |
| WO-2007067333-A2 | TRIOXANE DIMERS HAVING HIGH ANTICANCER AND LONG-LASTING ANTIMALARIAL ACTIVITIES | JOHNS HOPKINS UNIVERSITY (US) | 2007-06-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120172292-A1 | METHOD FOR PROTECTION OF ANTIMICROBIAL AND ANTICANCER DRUGS FROM INACTIVATION BY NITRIC OXIDE | NOS2, NOS1, NOS3 | ALDH1A1 1004/4885HSP90AA1 254/4885NPC1 1033/4885 |
| US-20090291923-A1 | TRIOXANE DIMERS HAVING HIGH ANTICANCER AND LONG-LASTING ANTIMALARIAL ACTIVITIES | HCCS, XPO5, DHX15 | ALDH1A1 4123/4885HSP90AA1 3239/4885NPC1 2555/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.